The first domestic and global cervical cancer vaccine industrialization project was launched in Xiamen Haishu. The cervical cancer vaccine (vaccine) has now entered the phase III clinical trial observation stage and will be put into production before 2018. The Phase II base of Xiamen Wantai Bohai Biotechnology Co., Ltd. was laid at the Xiamen Biomedical Port in Haishu. The first domestic and global third cervical cancer vaccine industrialization project was launched here. The cervical cancer vaccine (vaccine) has now entered the phase III clinical trial observation stage and will be put into production before 2018.
The base covers an area of ​​67,834.644 square meters and is an extension of the development and production base of Phase I. According to reports, Phase II base will be based on the research and development and production of innovative products such as hepatitis vaccine, cervical cancer vaccine, medical equipment and antibody drugs. The products have high starting point and advanced technology and equipment, leading the domestic industry.
It is reported that Xiamen Wantai Bohai Biotechnology Co., Ltd. is the only vaccine manufacturer in Fujian Province. It was established in 2005 and settled in Haishu in 2009. It is the whole of Beijing Wantai Biological Pharmaceutical Co., Ltd., which is controlled by Yangshengtang Co., Ltd. Subsidiary company.
The application of Phase II base will effectively promote the transition of cervical cancer vaccine from research and development to production stage, which will promote the development of Xiamen Biomedical Port and enhance the competitiveness of the industry.
The vibrant Xiamen Biomedical Port is bred with super energy. Last year, the output value exceeded 10 billion yuan, accounting for half of the city.
True & Bright Metal Packaging Co.,Ltd.KaiPing , https://www.tnbcan.com